Amakem initiates phase 2 study of investigational glaucoma agent

Amakem Therapeutics announced its initiation of a phase 2 dose-ranging study for the investigational glaucoma agent, AMA0076, according to a press release.The locally-acting Rho-kinase (ROCK) inhibitor has been developed to reduce IOP by targeting the main outflow system in the eye.

Full Story →